Klotho Neurosciences
Klotho Neurosciences is dedicated to developing innovative biologic, cell, and gene therapies to treat neurodegenerative diseases and age-related disorders. Their mission is to build a leading gene therapy company by advancing their patented α-Klotho gene therapy research and exploring new treatments and diagnostics for diseases like ALS, Alzheimer’s, and Parkinson’s. They focus on extending the reach of therapies to high unmet medical needs and aim to provide disruptive treatments to alleviate or reverse neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Klotho Neurosciences
Products
Gene therapy construct expressing secreted truncated Klotho (s-KL)
A gene construct encoding a secreted, truncated form of a human Klotho protein designed to produce therapeutic protein in vivo; described for delivery via viral vectors, lipid-complexed DNA, or as a basis for recombinant protein therapeutics.
Autologous cell therapy using transfected patient cells
Ex vivo transfection of patient-derived cells with a therapeutic gene construct followed by reinfusion as a cell therapy product.
Recombinant secreted protein therapeutic (s-KL)
Recombinant production of the secreted truncated Klotho protein for use as a biologic therapeutic to increase systemic or local protein levels.
Gene therapy construct expressing secreted truncated Klotho (s-KL)
A gene construct encoding a secreted, truncated form of a human Klotho protein designed to produce therapeutic protein in vivo; described for delivery via viral vectors, lipid-complexed DNA, or as a basis for recombinant protein therapeutics.
Autologous cell therapy using transfected patient cells
Ex vivo transfection of patient-derived cells with a therapeutic gene construct followed by reinfusion as a cell therapy product.
Recombinant secreted protein therapeutic (s-KL)
Recombinant production of the secreted truncated Klotho protein for use as a biologic therapeutic to increase systemic or local protein levels.
Services
Gene and cell therapy R&D
Research and development of gene constructs, delivery modalities, and autologous cell therapy approaches targeting neurodegenerative and age-related disorders.
Preclinical testing and animal model studies
Execution of preclinical efficacy studies in relevant animal models assessing neuroprotection, plaque clearance, and neuromuscular disease outcomes.
Licensing and partnership development
Negotiation and management of licensing agreements and research partnerships with academic institutions to expand the candidate portfolio and technology reach.
Regulatory strategy and engagement
Interactions with regulatory bodies including pursuit of orphan drug designation and related regulatory activities for gene therapy candidates.
Gene and cell therapy R&D
Research and development of gene constructs, delivery modalities, and autologous cell therapy approaches targeting neurodegenerative and age-related disorders.
Preclinical testing and animal model studies
Execution of preclinical efficacy studies in relevant animal models assessing neuroprotection, plaque clearance, and neuromuscular disease outcomes.
Licensing and partnership development
Negotiation and management of licensing agreements and research partnerships with academic institutions to expand the candidate portfolio and technology reach.
Regulatory strategy and engagement
Interactions with regulatory bodies including pursuit of orphan drug designation and related regulatory activities for gene therapy candidates.
Expertise Areas
- Cell and gene therapy development
- Neurodegenerative disease therapeutics (Alzheimer's, ALS, Parkinson's)
- Preclinical efficacy and animal model testing
- Vector design and delivery optimization
Key Technologies
- Gene therapy constructs (in vivo expression of therapeutic protein)
- Viral vector delivery
- Lipid-complexed DNA (non-viral) delivery
- Recombinant protein therapeutics